GleamWall
中文EN

AUPH Aurinia Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1600620 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY21.0%
TTM net income YoY303.7%
TTM EPS YoY308.9%
Revenue 3-yr CAGR26.5%
Net income 3-yr CAGR—

Margins

Gross margin90.6%
Operating margin48.6%
Net margin97.7%
FCF margin—
EBITDA margin54.6%

Returns

ROE61.4%
ROA46.4%
ROIC (approx.)34.6%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.12x
Interest coverage40.36x

Cash quality & payout

Operating cash flow / net income0.56x
Accruals ratio20.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q42025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue$83.70M$83.22M$77.70M$77.11M$73.47M$70.01M$62.47M$59.87M
Cost of revenue$8.31M$6.55M$6.50M$8.80M$8.18M$7.12M$8.57M$5.55M
Gross profit$75.39M$76.67M$71.20M$68.31M$65.29M$62.89M$53.89M$54.31M
R&D expense$16.61M$13.05M$7.47M$10.89M$8.44M$7.43M$5.74M$8.11M
SG&A expense$24.68M$23.51M$22.03M$29.25M$26.18M$26.02M$20.34M$37.03M
Operating income$35.36M$46.34M$41.42M$33.24M$29.75M$20.08M$21.85M-$1.67M
Interest expense$867,000$948,000$1.01M$1.05M$1.10M$1.12M$1.07M$1.15M
Pretax income$38.72M$48.79M$43.92M$35.69M$31.96M$22.16M$24.35M$1.17M
Income tax$7.01M$11.37M$9.57M-$175.10M$411,000$643,000$1.00M-$256,000
Net income$31.70M$37.41M$34.35M$210.79M$31.55M$21.51M$23.34M$1.43M
EBITDA$40.20M$51.17M$46.24M$38.10M$34.61M$24.95M$26.70M$3.19M
EPS (basic)0.240.290.261.600.240.160.170.01
EPS (diluted)0.230.280.251.530.230.160.160.01
Weighted avg. shares (diluted)135.17M133.53M137.64M—136.01M137.53M143.20M—
Balance sheet
Cash & equivalents$45.79M$179.73M$40.75M$80.21M$72.89M$52.91M$66.11M$83.43M
Inventory$43.73M$45.15M$46.41M$45.69M$44.79M$46.50M$46.20M$39.23M
Current assets$587.89M$541.32M$480.24M$491.97M$438.74M$408.97M$405.76M$446.60M
PP&E, net$1.74M$1.86M$1.99M$2.11M$2.27M$2.42M$2.58M$2.73M
Intangibles$3.17M$3.38M$3.59M$3.76M$3.90M$4.05M$4.16M$4.36M
Total assets$825.70M$792.26M$724.00M$751.59M$527.53M$502.56M$504.85M$550.64M
Current liabilities$96.00M$99.89M$86.56M$93.72M$76.22M$78.27M$68.41M$97.76M
Total liabilities$168.19M$177.40M$156.37M$170.26M$161.76M$167.26M$154.66M$173.17M
Shareholders' equity$657.52M$614.86M$567.63M$581.33M$365.77M$335.30M$350.19M$377.48M
Shares outstanding134.00M132.91M130.77M132.32M131.84M132.67M137.75M140.88M
Cash flow statement
Operating cash flow$46.37M$52.57M$32.56M$45.67M$44.45M$44.24M$1.30M$30.11M
Investing cash flow-$175.73M$81.45M-$18.08M-$36.76M-$13.77M-$13.27M$31.03M$39.22M
Financing cash flow-$4.32M$4.81M-$53.69M-$1.89M-$10.49M-$44.39M-$49.34M-$23.05M
Depreciation & amortization$4.84M$4.83M$4.82M$4.86M$4.87M$4.86M$4.86M$4.86M
Stock-based compensation$6.12M$2.84M-$866,000$6.73M$5.92M$5.44M-$3.41M$8.95M
Share buybacks$0$38.72M$36.16M$0$8.67M$42.56M$46.92M$21.80M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.